Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations: 2024-2025

Historic Cash from Operations for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$80.6 million.

  • Kura Oncology's Cash from Operations fell 85.61% to -$80.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year change of. This contributed to the annual value of $134.3 million for FY2024, which is 207.61% up from last year.
  • Latest data reveals that Kura Oncology reported Cash from Operations of -$80.6 million as of Q3 2025, which was down 180.18% from -$28.8 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Cash from Operations ranged from a high of $269.1 million in Q4 2024 and a low of -$80.6 million during Q3 2025.